Who are KPI-121 Ophthalmic Suspension's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kpi-121-ophthalmic-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

KPI-121 Ophthalmic Suspension — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KPI-121 Ophthalmic Suspension (KPI-121 Ophthalmic Suspension) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TRPV1 antagonist / Topical anti-inflammatory. Area: Ophthalmology.

phase 3 TRPV1 antagonist / Topical anti-inflammatory TRPV1 (Transient Receptor Potential Vanilloid 1) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

KPI-121 Ophthalmic Suspension (KPI-121 Ophthalmic Suspension) — Kala Pharmaceuticals, Inc.. KPI-121 is a topical ophthalmic suspension that reduces ocular inflammation and promotes corneal healing through inhibition of transient receptor potential vanilloid 1 (TRPV1) and modulation of inflammatory pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
KPI-121 Ophthalmic Suspension TARGET	KPI-121 Ophthalmic Suspension	Kala Pharmaceuticals, Inc.	phase 3	TRPV1 antagonist / Topical anti-inflammatory	TRPV1 (Transient Receptor Potential Vanilloid 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TRPV1 antagonist / Topical anti-inflammatory class)

Kala Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KPI-121 Ophthalmic Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/kpi-121-ophthalmic-suspension. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab